|Bid||764.20 x 0|
|Ask||764.50 x 0|
|Day's Range||752.60 - 766.60|
|52 Week Range||544.30 - 766.60|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||449.82|
|Forward Dividend & Yield||25.52 (3.39%)|
|1y Target Est||93.83|
AstraZeneca stock surged Thursday after the drug giant crushed fourth-quarter earnings and revenue expectations, and said sales will accelerate by a high single-digit percentage in 2019.
The FTSE 100 added 0.1 percent, outperforming its U.S. and European peers, though the FTSE 250 was down 0.4 percent as ConvaTec tanked after reporting what its CEO called "disappointing results". Investors also kept an eye on the ongoing parliamentary turmoil over Prime Minister Theresa May's Brexit plan. "The fact that there will now be another meaningful vote on Feb. 27 has taken the pressure off today's vote ... but Theresa May's 'my deal or no deal' doesn't look like it will make it into next month," London Capital Group analyst Jasper Lawler said.
European shares gave up three-month highs on Thursday after a surprise sharp decline in U.S. retail sales pulled stocks lower in afternoon trading, spoiling an initially upbeat session that saw blue-chips such as Nestle shine on strong earnings. Wall Street opened in the red, albeit moderately, after data showing the largest drop in retail sales since September 2009, when the economy was emerging from a recession. "The market’s fragile optimism was undermined on Thursday after a truly horrendous set of retail sales figures out of the U.S.," wrote Connor Campbell, an analyst at Spreadex.
European shares gave up three-month highs on Thursday after a surprise sharp decline in U.S. retail sales pulled stocks lower in afternoon trading, spoiling an initially upbeat session that saw blue-chips such as Nestle shine on strong earnings. The pan-European STOXX 600 closed down 0.2 percent after spending the first half of the day in positive territory. Wall Street opened in the red, albeit moderately, after data showing the largest drop in retail sales since September 2009, when the economy was emerging from a recession.
PLC, battered by a string of patent expiries in recent years, reported its strongest sales growth since 2009 as efforts to replenish its pipeline and pivot toward cancer drugs started to pay off. The Cambridge, England-based drugmaker said product sales rose 4% to $21 billion in 2018 and that growth would accelerate this year, forecasting a high single-digit percentage increase. Thursday’s results could mark a turning point for AstraZeneca.
Shares in AstraZeneca, which reported better than expected fourth-quarter results, were up 5.1 percent to 6,015 pence by 1040 GMT, on track for their best day in more than 18 months. After a sharp sales fall following his appointment in 2012 due to the expiry of major patents, the results were the latest vindication of Chief Executive Officer Pascal Soriot's strategy for rebooting the British drugmaker. Sales of cancer drugs Tagrisso, Imfinzi and Lynparza were central to the gains, with oncology sales rising 61 percent to $1.78 billion (£1.39 billion).
On a per-share basis, the Cambridge, Britain-based company said it had net income of 82 cents. Earnings, adjusted for non-recurring costs, were $1.58 per share. The results exceeded Wall Street expectations. ...
AstraZeneca shares traded sharply higher Thursday after the U.K.-based drugmaker posted stronger-than-forecast fourth quarter earnings, and said 2019 revenues would continue to rise, thanks to increasing ...
PLC (AZN.LN) reported Thursday its first year of meaningful sales growth since 2009 and said it expected a sharper rise this year, as efforts to replenish the pipeline and pivot toward cancer drugs start to pay off. The Cambridge, England-based drugmaker said product sales edged up 4% to $21 billion in 2018, marking a turning point for the company after years of patent expiries hammered its performance. It said it expected growth to accelerate this year, guiding for a high-single-digit percentage increase in product sales in 2019.
in the third quarter of 2018, the Anglo-Swedish group continued the run — as expected — in its final quarter, posting an 8 per cent rise in product sales after stripping out currency fluctuations and a 5 per cent rise on a reported basis to $5.77bn. Shares in the FTSE 100-listed group were 7 per cent higher in Thursday afternoon trade after Pascal Soriot, chief executive, hailed the company’s first year of sales growth since 2009 and said he was confident that 2019 would see “our earnings, not just our sales, return to growth”.
Pfizer, Merck and Sanofi have agreed to send their CEOs to Washington. AstraZeneca said it is reviewing the request. Bristol-Myers Squibb and Johnson & Johnson have not said whether they'll testify.
Pharmaceutical executives have already declined the Senate Finance Committee's invitation to testify about drug prices. Sen. Ron Wyden floated this possibility of issuing a subpoena forcing them to testify.
Britain's AstraZeneca said a potential medicine to prevent respiratory syncytial virus (RSV) in babies and infants had been granted special status by U.S. and European regulators, designed to speed up the development of novel and better drugs. The "Breakthrough Therapy" and "Prime" designations in the United States and Europe respectively were based on early results from Phase IIb trials of MEDI8897, AstraZeneca said. The drug is being developed for use in a broader infant population than the standard of care for RSV prevention, Synagis, which needs monthly injections and is therefore only approved in Europe for high-risk infants.
Jan 16 (Reuters) - Luye Pharma Group Ltd: * LUYE PHARMA REACHES STRATEGIC PARTNERSHIP WITH ASTRAZENECA, STRENGTHENS COMMITMENT TO CARDIOVASCULAR THERAPEUTIC FIELD * LUYE PHARMA GROUP LTD - GRANTS ASTRAZENECA ...
Jan 16 (Reuters) - Luye Pharma Group Ltd: * ANNOUNCES GRANT OF PROMOTION RIGHT OF XUEZHIKANG CAPSULES IN MAINLAND CHINA TO ASTRAZENECA Source text for Eikon: Further company coverage:
AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.
AstraZeneca PLC has appointed José Baselga, a prominent but controversial cancer doctor, to lead oncology research and development as part of a wider overhaul designed to get drugs to market faster. AstraZeneca Chief Executive Pascal Soriot said in an interview that the company’s chief ethics officer was satisfied that these omissions were accidental, as Dr. Baselga has maintained since his failures were highlighted in a New York Times report in September.
The 59-year-old Spaniard resigned as chief medical officer of Memorial Sloan Kettering Cancer Center in September after the New York Times and Pro Publica revealed that he had not disclosed millions of dollars in payments from healthcare firms. Baselga told Reuters he accepted he had "failed to make the appropriate disclosures" in a number of articles and had corrected them, while a spokesman said the validity of his research was not under question and AstraZeneca viewed the episode as over. Baselga, who last year acknowledged a failure to disclose his links to companies in his medical journal articles and at professional meetings, also resigned from the board of Bristol-Myers Squibb (BMY.N) at the time.
AstraZeneca Plc has appointed José Baselga to head research and development for oncology as it looks to align the unit with its commercial operations to drive growth. Baselga resigned as Memorial Sloan ...